Product Description
Mechanisms of Action: GDF8 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: Eastern America
Company Founding Year: 1849
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Muscular Dystrophy, Becker|Muscular Dystrophy, Facioscapulohumeral|Muscular Dystrophy, Duchenne|Muscular Dystrophies, Limb-Girdle
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00563810 |
3147K1-103 | P1 |
Completed |
Healthy Volunteers |
None |
2019-03-22 |
Treatments |
|
2004-000622-67 |
2004-000622-67 | P2 |
Completed |
Muscular Dystrophies, Limb-Girdle|Muscular Dystrophy, Becker|Muscular Dystrophy, Facioscapulohumeral |
2007-01-31 |
2022-03-12 |
Treatments |
|
NCT00104078 |
3147K2-101 | P2 |
Completed |
Muscular Dystrophy, Becker|Muscular Dystrophy, Facioscapulohumeral|Muscular Dystrophy, Duchenne|Muscular Dystrophies, Limb-Girdle |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/03/2023 |
PubMed |
Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD): A Systematic Review. |
|
05/18/2021 |
PubMed |
Current and Future Therapeutic Strategies for Limb Girdle Muscular Dystrophy Type R1: Clinical and Experimental Approaches. |